{
  "run_date": "2026-02-07T19:54:03.252026+00:00",
  "stocks_scanned": 235,
  "top_picks": [
    {
      "ticker": "TKA",
      "name": "thyssenkrupp AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 11.655,
      "currency": "EUR",
      "market_cap": 9659455488,
      "pe_ratio": 15.54,
      "forward_pe": 10.92704,
      "roe": 5.0869998,
      "dividend_yield": 129.0,
      "momentum_6m": 19.602403566203286,
      "momentum_12m": 157.50894348275168,
      "rsi_14": 66.40772694967322,
      "alpha_score": 82,
      "score_breakdown": {
        "value": 21,
        "quality": 15,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 8
      },
      "yahoo_url": "https://finance.yahoo.com/quote/TKA.DE",
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "thyssenkrupp demonstrates solid momentum from recent stock gains and projected net income stability around 464M EUR in 2026, alongside earnings growth outpacing the metals and mining industry at 26% annually.[5][6] However, limited visibility into last 30 days' operational news and upcoming Q1 results introduce uncertainty in a challenging macroeconomic environment, balancing transformation progress against modest ROE of 5.1%.[2][5]",
      "company_overview": "thyssenkrupp AG is a diversified German industrial conglomerate operating in sectors like steel, automotive components, engineering, and materials, with a fiscal year running from October 1 to September 30.[1][2] The company is actively pursuing its transformation strategy amid macroeconomic challenges, as evidenced by strong recent stock performance (6m +19.6%, 12m +157.5%) and projected earnings growth.[2][5] Its current business situation reflects ongoing restructuring, with the 27th Annual General Meeting held on January 30, 2026, and preparation for the Q1 2025/2026 interim report.[1][2]",
      "key_developments": [
        "Annual General Meeting occurred on January 30, 2026, marking a key corporate governance event post-fiscal year start.[2]",
        "Closed period for insider trading active from January 13 to February 12, 2026, ahead of Q1 results, indicating routine compliance with no reported disruptions.[1]",
        "Quiet period from January 21 to February 11, 2026, limiting capital market dialogue prior to Q1 interim report publication on February 12, 2026.[1][2]"
      ],
      "catalysts": [
        "Publication of Q1 2025/2026 interim report (October-December) on February 12, 2026, with live analyst conference call at 11:00 CET featuring CEO Miguel \u00c1ngel L\u00f3pez and CFO Dr. Axel Hamann.[1][2][3]",
        "Potential post-Q1 guidance updates on transformation strategy and segment performance, given the company's focus on driving change.[2]"
      ],
      "risk_factors": [
        "Macroeconomic pressures impacting industrial sectors, as thyssenkrupp continues transformation in a \"challenging and rapidly changing\" environment.[2]",
        "Weaker-than-expected Q1 results or guidance, with closed/quiet periods signaling high sensitivity around February reporting.[1][2]"
      ],
      "sources": [
        "https://www.thyssenkrupp.com/en/investors/calendar",
        "https://www.thyssenkrupp.com/en/investors",
        "https://www.thyssenkrupp.com/en/investors/reporting-and-publications",
        "https://www.marketscreener.com/quote/stock/THYSSENKRUPP-AG-436698/finances/",
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/past",
        "https://eulerpool.com/en/stock/thyssenkrupp-Stock-DE0007500001/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "EN",
      "name": "Bouygues SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 48.25,
      "currency": "EUR",
      "market_cap": 18544437248,
      "pe_ratio": 17.545454,
      "forward_pe": 13.719469,
      "roe": 8.397,
      "dividend_yield": 415.00000000000006,
      "momentum_6m": 25.84767816372373,
      "momentum_12m": 60.73101046194995,
      "rsi_14": 69.28839450740628,
      "alpha_score": 78,
      "score_breakdown": {
        "value": 21,
        "quality": 9,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/EN.PA",
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "Bouygues demonstrates resilient growth across segments, with confirmed 2025 guidance, strong backlog in construction, and strategic telecom consolidation via the SFR bid positioning it for market share gains in a consolidating French sector.[2] Recent UK digitalization expansion and robust H1 2025 results (sales up 1.3%) support momentum, aligning with 60.7% 12-month returns and positive technical signals like short-term buy from moving averages.[1][2] At P/E 17.5 and 4.91% dividend yield, valuation remains attractive versus peers amid European industrials recovery.[2]",
      "company_overview": "Bouygues SA is a diversified French conglomerate operating in construction, telecom (Bouygues Telecom), and media, with a strong market position in Europe evidenced by a \u20ac57.15B trailing twelve-month revenue and \u20ac1.05B net income.[2] The company reported robust 2024 full-year results with \u20ac56.8B sales (up 1% YoY) and current operating profit of \u20ac2,535M, alongside H1 2025 sales of \u20ac26.9B (up 1.3% YoY), confirming its 2025 outlook despite macroeconomic uncertainty.[2] Shares have delivered strong performance with a 6-month return of +25.8% and 12-month return of +60.7%, trading at a P/E of 17.5 amid positive momentum (Alpha Score 78/100).[user query]",
      "key_developments": [
        "On February 5, 2026, Bouygues expanded procurement digitalization into the UK via a ProcurePro partnership, enhancing construction efficiency.[2]",
        "Bouygues Telecom, alongside Orange and Free (Iliad), submitted a joint non-binding \u20ac17B offer to acquire major Altice France telecom assets including SFR, potentially reshaping the French market.[2]",
        "Monthly share disclosure on February 2, 2026, reported 385M shares outstanding with 497M theoretical voting rights, indicating stable capital structure.[3]",
        "Stock gained 0.364% on February 3, 2026 (US ADR BOUYY to $11.02), reflecting short-term upward trend with projected 5.92% rise over next 3 months.[1]"
      ],
      "catalysts": [
        "Potential SFR/Altice deal progression or binding offer announcement, boosting Bouygues Telecom revenue and synergies (expected in H1 2026).[2]",
        "Q1 2026 or full H1 2026 earnings releases (following Nov 5, 2025 earnings date pattern), with reaffirmed guidance amid high construction backlog.[2]",
        "UK ProcurePro rollout outcomes, driving construction margins in a post-Brexit recovery context.[2]"
      ],
      "risk_factors": [
        "Macroeconomic and geopolitical uncertainty impacting construction/telecom demand, as noted in company outlooks.[2]",
        "SFR bid failure or regulatory hurdles in French telecom consolidation, exposing to competitive pressures.[2]",
        "Low trading volume divergence signaling potential short-term pullbacks, with support at \u20ac8.91-9.03 (US ADR equivalent).[1]"
      ],
      "sources": [
        "https://stockinvest.us/stock/BOUYY",
        "https://stockanalysis.com/quote/fra/BYG/",
        "https://www.globenewswire.com/news-release/2026/02/02/3230458/0/en/bouygues-monthly-disclosure-of-the-total-number-of-shares-and-voting-rights.html",
        "https://ng.investing.com/equities/bouygues-n-historical-data"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AZN",
      "name": "AstraZeneca PLC",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 14104.0,
      "currency": "GBP",
      "market_cap": 218651983872,
      "pe_ratio": 31.623316,
      "forward_pe": 18.560966,
      "roe": 21.674,
      "dividend_yield": 173.0,
      "momentum_6m": 27.799927509967382,
      "momentum_12m": 20.387470630408732,
      "rsi_14": 54.043839758125465,
      "alpha_score": 75,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AZN.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AstraZeneca demonstrates sustained growth across core franchises, a deep pipeline with blockbuster potential, and strategic moves like NYSE listing to enhance liquidity and investor access, supporting its 2030 revenue ambitions.[1][2] Analyst consensus rates it a 'strong buy' with upside to 14,812p, reinforced by strong cash flows for dividends/buybacks and oncology leadership despite near-term margin scrutiny.[1] Recent share performance and medium-term uptrend remain intact, positioning AZN for outperformance in a competitive pharma landscape.[1]",
      "company_overview": "AstraZeneca PLC is a leading global biopharmaceutical company focused on oncology, cardiovascular, renal & metabolism (CVRM), and respiratory & immunology (R&I) franchises, with strong momentum in products like Tagrisso, Enhertu, and Farxiga driving double-digit growth.[1] The company maintains a robust late-stage pipeline and recently harmonized its global listings by adding ordinary share trading on the NYSE under the AZN ticker alongside LSE and Nasdaq Stockholm.[2] Shares have risen ~24% over the past year, trading near record highs with a consensus analyst price target ~7% above current levels and a 'strong buy' rating.[1]",
      "key_developments": [
        "Began trading ordinary shares on the NYSE under AZN ticker, replacing prior American Depositary Shares, to access the world's largest capital market and broaden investor base while retaining LSE and Stockholm listings.[2]",
        "Reaffirmed long-term ambition of $80 billion in annual revenue by 2030 and launching 20 new medicines, citing pipeline readouts with over $10 billion peak revenue potential.[2]",
        "Upcoming full-year 2025 results on 10 February 2026 expected to show solid revenue and EPS growth, with focus on oncology momentum, margin sustainability, and 2026 guidance amid US/Europe pricing pressures.[1]"
      ],
      "catalysts": [
        "Full-year 2025 earnings release on 10 February 2026, with updates on revenue growth, oncology uptake, pipeline progress (e.g., regulatory submissions, trial milestones), and 2026 guidance.[1]",
        "Pipeline readouts and potential approvals/label expansions in oncology, CVRM, and rare diseases, representing over $10 billion peak revenue opportunity.[1][2]"
      ],
      "risk_factors": [
        "Pricing and reimbursement pressures in the US and Europe potentially impacting margins and product demand in key franchises like oncology and CVRM.[1]",
        "Earnings misses on revenue growth, profitability, or guidance if oncology momentum slows or R&D costs escalate in a competitive biotech environment.[1]"
      ],
      "sources": [
        "https://www.ig.com/uk/news-and-trade-ideas/_astrazeneca-full-year-earnings--can-the-pharma-giant-maintain-o-260204",
        "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-5cf8521c5fa8.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "FERG",
      "name": "Ferguson Enterprises Inc.",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Industrials",
      "price": 19170.0,
      "currency": "GBP",
      "market_cap": 38471598080,
      "pe_ratio": 26.260273,
      "forward_pe": 23.096275,
      "roe": 33.404,
      "dividend_yield": 138.0,
      "momentum_6m": 16.616244059754326,
      "momentum_12m": 31.685590830856224,
      "rsi_14": 64.28571428571428,
      "alpha_score": 71,
      "score_breakdown": {
        "value": 9,
        "quality": 22,
        "momentum": 25,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/FERG.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "**BULLISH** - **Confidence: HIGH**   Ferguson's execution remains strong, with margin expansion, non-residential tailwinds, and disciplined capital allocation supporting outperformance despite residential headwinds and economic uncertainty. Updated FY2025 guidance affirms ~5% revenue growth and 9.4-9.6% operating margins, underpinned by a robust balance sheet enabling M&A and buybacks. High ROE (33.4%) and momentum (Alpha 71/100) position it well for continued market share gains in a structurally underbuilt U.S. housing/infrastructure backdrop.[1][2][3]",
      "company_overview": "",
      "key_developments": [
        "Reported Q1 FY2026 net sales of $8.2B (+5.1% YoY, 4.2% organic), gross margin 30.7% (+60bps), adjusted operating profit $808M (+14.4%), and adjusted EPS $2.84 (+15.9%), beating revenue and some EPS consensus but missing higher expectations, leading to a ~4% premarket stock drop on Dec 9, 2025.[1][2][3][4][8]",
        "Strong non-residential growth (12% overall, 21% in Commercial/Mechanical, 14% in Waterworks) offset residential weakness (-1%, HVAC -6%), with U.S. sales up 5.3% and Canada up 2.2%; acquired Moore Supply to bolster Chicago HVAC.[1][2][3][4]",
        "Returned $372M to shareholders ($208M repurchases, 7% dividend hike to $0.89/share); strong balance sheet (net debt/EBITDA 1.1x), free cash flow $325M (+18.6%).[1][2][3][4]"
      ],
      "catalysts": [
        "Q2 FY2026 earnings (expected ~March 2026) to validate non-residential momentum and guidance progress amid potential housing recovery signals.[3][5]",
        "Further M&A leveraging $800M repurchase authorization remainder and low leverage; multi-year tailwinds from public works, aging infrastructure, and non-residential projects.[1][2][3][4]"
      ],
      "risk_factors": [
        "Persistent residential weakness from soft housing starts, low permits, and RMI activity, plus HVAC transition challenges, could pressure ~50% of U.S. sales.[3][4]",
        "Macro uncertainty (e.g., interest rates, economic slowdown) impacting non-residential capex; Canadian segment margin contraction (-30.4% in Q1).[2][3]"
      ],
      "sources": [
        "https://www.moomoo.com/news/post/62629271/ferguson-enterprises-inc-ferg-q1-2026-earnings-call-transcript-summary",
        "https://quartr.com/companies/ferguson-enterprises-inc_3672",
        "https://www.investing.com/news/company-news/ferguson-q1-2026-slides-eps-miss-triggers-stock-decline-despite-revenue-beat-93CH-4398910",
        "https://www.youtube.com/watch?v=ZKruzocZHyc",
        "https://www.corporate.ferguson.com/investor/events-results-and-reports/default.aspx",
        "https://www.corporate.ferguson.com/investor/why-ferguson/default.aspx",
        "https://www.corporate.ferguson.com/pressroom/news-releases/news-details/2025/Ferguson-Reports-Quarter-Ended-October-31-2025/default.aspx",
        "https://www.marketbeat.com/stocks/NYSE/FERG/earnings/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "ENR",
      "name": "Siemens Energy AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 152.0,
      "currency": "EUR",
      "market_cap": 130012315648,
      "pe_ratio": 95.0,
      "forward_pe": 28.98324,
      "roe": 16.816,
      "dividend_yield": 46.0,
      "momentum_6m": 58.33333333333333,
      "momentum_12m": 166.19965685093595,
      "rsi_14": 71.95574684426185,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 23,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/ENR.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Siemens Energy AG is a Germany-based energy technology company supplying equipment and services across power generation, grids, and energy-transition projects.[1] The company has undergone a dramatic turnaround, with its share price recovering from \u20ac13.85 in early February 2024 to approximately \u20ac143.51 by early February 2026, driven by stronger financial performance including double-digit comparable revenue growth, record order intake, and an upgraded mid-term outlook through 2028.[1] The stock has gained 186% over the past 12 months, reflecting investor confidence in the company's execution and exposure to structural demand for grid and energy-transition infrastructure.[2]",
      "company_overview": "Siemens Energy AG is a Germany-based energy technology company supplying equipment and services across power generation, grids, and energy-transition projects.[1] The company has undergone a dramatic turnaround, with its share price recovering from \u20ac13.85 in early February 2024 to approximately \u20ac143.51 by early February 2026, driven by stronger financial performance including double-digit comparable revenue growth, record order intake, and an upgraded mid-term outlook through 2028.[1] The stock has gained 186% over the past 12 months, reflecting investor confidence in the company's execution and exposure to structural demand for grid and energy-transition infrastructure.[2]",
      "key_developments": [
        "**Upgraded guidance and record orders**: Deutsche Bank Research raised its ENR price target to \u20ac170 from \u20ac135, citing improved fundamentals, stronger earnings outlook, and a more favorable view of the company's order pipeline and profitability.[1] Jefferies similarly raised its target to \u20ac164 from \u20ac134, pointing to improved earnings visibility and supportive sector dynamics.[1]"
      ],
      "catalysts": [
        "**Execution on order backlog**: Conversion of record orders into revenue and margin expansion will be critical to justify current valuations and support analyst price targets of \u20ac164-\u20ac170."
      ],
      "risk_factors": [
        "**Valuation stretched relative to growth**: Revenue growth forecasts of 12% annually match the broader industry, yet the stock trades at a significant premium to peers, creating vulnerability to sentiment shifts or execution missteps.[2]"
      ],
      "sources": [
        "https://capital.com/en-int/analysis/siemens-energy-stock-forecast",
        "https://simplywall.st/stocks/de/capital-goods/etr-enr/siemens-energy-shares/news/siemens-energy-ags-etrenr-26-price-boost-is-out-of-tune-with",
        "https://www.marketscreener.com/quote/stock/SIEMENS-ENERGY-AG-113080700/",
        "https://www.siemens-energy.com/global/en/home/investor-relations.html",
        "https://www.perplexity.ai/finance/ENR.DE"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "SAF",
      "name": "Safran SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 308.0,
      "currency": "EUR",
      "market_cap": 128284680192,
      "pe_ratio": 29.758453,
      "forward_pe": 29.628347,
      "roe": 34.745997,
      "dividend_yield": 94.0,
      "momentum_6m": 5.987609611503686,
      "momentum_12m": 26.409959646058656,
      "rsi_14": 39.782594994443805,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 20,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/SAF.PA",
      "signal": "HOLD",
      "confidence": "MEDIUM",
      "reasoning": "Safran's robust fundamentals (ROE 27.93%, strong interest coverage of 51.92%) and aerospace leadership support stability, but elevated P/E (38.74 vs. peers RTX 31.82, GE 46.84) and premium pricing limit upside without catalysts.[1] Global aerospace demand remains positive via CFM engines, yet lack of recent news and medium uncertainty warrant caution over 3-6 months.[1] Peers like GE and RTX show comparable quality metrics, suggesting no clear edge.[1]",
      "company_overview": "**Safran SA** is a leading global player in aerospace propulsion and equipment, with three key segments: aerospace propulsion (including CFM joint venture engines with GE for narrow-body aircraft), aircraft equipment/defense/aerosystems (landing gear, avionics), and aircraft interiors (seats, cabins).[1] The company holds a strong market position in commercial and military aerospace, employing 96,390 people, with a market cap of \u20ac125.20B and trading as a large-growth stock at \u20ac298.60-308 (recent close +1.82%).[1][3] Recent performance shows stability amid volatility, with shares in the 52-week range of \u20ac190.70\u2013329.80 and key metrics including P/E 38.74, ROE 27.93%, and dividend yield ~0.97%.[1]",
      "key_developments": [
        "Stock price rose +1.82% to 308\u20ac on Feb 6, 2026, with intraday range \u20ac298.10\u2013302.40 and recent trading around 299-305\u20ac (Feb 2-5).[1][2][3]",
        "No major company-specific news reported in the last 30 days; shares exhibit modest volatility with daily changes of -0.46% to +1.85% in early February.[2]",
        "Trading at a 546% premium to Morningstar's fair value of \u20ac391, reflecting high valuation amid medium uncertainty and a narrow economic moat.[1]"
      ],
      "catalysts": [
        "Potential Q4/full-year 2025 earnings release or guidance update, driving visibility into propulsion backlog and CFM deliveries.[1]",
        "Aerospace sector recovery signals, such as Airbus/Boeing order announcements boosting engine/interiors demand.[1]"
      ],
      "risk_factors": [
        "High valuation (P/E 38.74, Price/Sales 4.19) vulnerable to aerospace supply chain disruptions or weakening air travel demand.[1]",
        "Medium uncertainty rating and narrow moat expose to geopolitical/military spending shifts affecting defense segment.[1]"
      ],
      "sources": [
        "https://www.morningstar.com/stocks/xpar/saf/quote",
        "https://www.investing.com/equities/safran-historical-data",
        "https://www.safran-group.com/finance/safran-share-price",
        "https://finbox.com/ENXTPA:SAF/",
        "https://www.safran-group.com/finance/glance",
        "https://markets.ft.markitdigital.com/data/equities/tearsheet/historical?s=SAF%3APAR"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "GSK",
      "name": "GSK plc",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 2198.0,
      "currency": "GBP",
      "market_cap": 88211988480,
      "pe_ratio": 15.812949,
      "forward_pe": 11.246936,
      "roe": 43.310001,
      "dividend_yield": 328.0,
      "momentum_6m": 56.58391015225654,
      "momentum_12m": 50.047182405412705,
      "rsi_14": 85.63432835820896,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 19,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/GSK.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "**BULLISH** - **Confidence: HIGH**   GSK's strong 2025 performance, led by double-digit Specialty Medicines growth and robust cash flow, supports sustained momentum into 2026 with guided 7-9% core EPS expansion and long-term \u00a340 billion+ sales target.[1][2][6] New CEO leadership, dividend hikes, buybacks, and recent Phase III successes signal operational delivery and pipeline progress, justifying the stock's 50%+ 12m return and re-rating to 26-year highs despite moderate near-term sales guidance.[5][7] At a P/E of 15.8 with 43.3% ROE, valuation remains attractive relative to growth prospects in a stable healthcare sector.[user metrics]",
      "company_overview": "**  \nGSK plc is a leading global biopharma company focused on Specialty Medicines (including Respiratory, Immunology & Inflammation, Oncology, and HIV), Vaccines, and General Medicines, with 2025 total sales of \u00a332.7 billion (+4% AER, +7% CER) driven by 17% growth in Specialty Medicines to \u00a313.5 billion.[1][2][6] The company reported strong full-year 2025 performance, including core operating profit up 11% to \u00a39.8 billion and core EPS up 12% to 172.0p, alongside robust cash generation of \u00a38.9 billion from operations.[1][2] Shares recently hit a 26-year high near \u00a320-\u00a321 following Q4 results, reflecting a market re-rating amid positive momentum under new CEO Luke Miels.[5][7]",
      "key_developments": [
        "Reported strong FY 2025 results on February 4, 2026: Q4 turnover +6% AER to \u00a38.6 billion, core EPS +14% CER to 25.5p; full-year Specialty Medicines +17%, Vaccines +2%, with Trelegy sales +13%.[1][2][6]",
        "Issued 2026 guidance: turnover growth 3-5% CER, core operating profit and core EPS growth 7-9% CER; reaffirmed 2031 sales outlook >\u00a340 billion.[1][2][3][5][6]",
        "Declared increased dividends (Q4 18p, FY 2025 66p, FY 2026 expected 70p) and executed \u00a31.4 billion of a \u00a32 billion share buyback; shares jumped 4-7% post-results to multi-decade highs.[1][2][5][7]",
        "Announced positive Phase III results for two pivotal trials (B-Well 1 and 2) in January 2026, strengthening R&D pipeline in Oncology and Vaccines.[6]"
      ],
      "catalysts": [
        "Commercial launches and R&D acceleration in Specialty Medicines, Oncology, and Vaccines, building on 2026 guidance execution.[1][2][6]",
        "Phase III trial readouts and potential approvals from January 2026 B-Well results, plus IP settlements boosting royalty income.[6]",
        "Completion of \u00a32 billion share buyback and progressive dividend policy amid strong free cash flow.[2]"
      ],
      "risk_factors": [
        "Slower 2026 sales growth (3-5%) due to expected low single-digit declines in Vaccines and General Medicines, plus looming HIV patent losses from 2028.[5]",
        "External pressures like U.S. tariff policies under Trump and pricing headwinds in key markets impacting legacy portfolio.[4][5]"
      ],
      "sources": [
        "https://www.nasdaq.com/articles/gsk-q4-results-climb-sees-growth-fy26-backs-2031-sales-view-update",
        "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/",
        "https://www.gurufocus.com/news/8580044/gsk-projects-moderate-growth-in-turnover-and-earnings-by-2026?mobile=true",
        "https://www.ig.com/uk/news-and-trade-ideas/gsk-full-year-earnings--can-the-pharma-giant-deliver-on-post-dem-260203",
        "https://www.voxmarkets.com/articles/gsk-sees-slower-sales-growth-in-2026-as-patent-loss-looms-7c4f7f2",
        "https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf",
        "https://kalkine.co.uk/news/premium/gsk-plc-at-a-26-year-high-is-the-market-re-rating-the-stock"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "RIO",
      "name": "Rio Tinto Group",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Basic Materials",
      "price": 6843.0,
      "currency": "GBP",
      "market_cap": 111193030656,
      "pe_ratio": 14.716128,
      "forward_pe": 12.113603,
      "roe": 17.158002,
      "dividend_yield": 416.0,
      "momentum_6m": 49.673994048695945,
      "momentum_12m": 36.53139134072427,
      "rsi_14": 66.68874172185431,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 22,
        "momentum": 25,
        "catalyst": 0,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/RIO.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Rio Tinto is the world's leading diversified mining company with a market capitalization of approximately $151.14 billion[1]. The company operates major assets including Pilbara iron ore operations, a 30% stake in the Escondida copper mine, and 66% ownership of the Oyu Tolgoi copper mine in Mongolia[1]. Rio Tinto has demonstrated strong financial performance with trailing twelve-month revenue of $53.73 billion, a robust operating margin of 25.39%, and net income of $12.66 billion in 2026 (up 16.61% year-over-year)[1][7].",
      "company_overview": "Rio Tinto is the world's leading diversified mining company with a market capitalization of approximately $151.14 billion[1]. The company operates major assets including Pilbara iron ore operations, a 30% stake in the Escondida copper mine, and 66% ownership of the Oyu Tolgoi copper mine in Mongolia[1]. Rio Tinto has demonstrated strong financial performance with trailing twelve-month revenue of $53.73 billion, a robust operating margin of 25.39%, and net income of $12.66 billion in 2026 (up 16.61% year-over-year)[1][7].",
      "key_developments": [
        "**Merger Collapse with Glencore**: Rio Tinto and Glencore abandoned merger talks on February 5, 2026, after failing to reach agreement by a U.K. regulatory deadline[3]. The primary sticking points were disagreements over leadership roles (Rio insisted on maintaining both Chair and CEO positions) and valuation, with Glencore arguing Rio's offer underestimated its value, particularly in copper and synergy benefits[1][3]."
      ],
      "catalysts": [
        "**2025 Annual Results Announcement**: Scheduled for February 19, 2026, this will provide detailed guidance on copper production growth, capital allocation plans, and strategic priorities post-merger[5]."
      ],
      "risk_factors": [
        "**Commodity Price Volatility**: Rio Tinto's earnings are highly sensitive to fluctuating commodity prices, particularly iron ore and copper[1]. Recent revenue growth has declined 3.9% over three years despite strong margins[1]."
      ],
      "sources": [
        "https://www.gurufocus.com/news/8586961/rio-tinto-rio-declines-offer-maintaining-independence",
        "https://simplywall.st/stocks/gb/materials/lse-rio/rio-tinto-group-shares/news/has-the-market-fully-reflected-rio-tinto-lserios-strong-rece",
        "https://www.morningstar.com/news/marketwatch/2026020614/whats-next-for-rio-tinto-and-glencore-after-260-billion-megamerger-aborted",
        "https://www.riotinto.com/en/invest/financial-calendar",
        "https://www.riotinto.com/en/invest/financial-news-performance",
        "https://www.riotinto.com/en/invest/reports",
        "https://eulerpool.com/en/stock/Rio-Tinto-Stock-GB0007188757/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AMAT",
      "name": "Applied Materials, Inc.",
      "exchange": "US",
      "index": "NASDAQ_SELECT",
      "sector": "Technology",
      "price": 322.51,
      "currency": "USD",
      "market_cap": 255983124480,
      "pe_ratio": 37.15553,
      "forward_pe": 26.492924,
      "roe": 35.508,
      "dividend_yield": 56.99999999999999,
      "momentum_6m": 75.29524861161806,
      "momentum_12m": null,
      "rsi_14": 48.28819156800613,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 17,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AMAT",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Applied Materials benefits from durable AI infrastructure demand, recurring revenue from equipment services, and strong analyst support with price targets well above current levels (~$315-$400 consensus), positioning it for outperformance in the semiconductor equipment space.[1][2][4] Recent earnings beats, robust ROE (35.5-39.26%), and guidance for Q1 FY2026 EPS of $1.98-$2.38 support sustained growth, even with modest YoY revenue declines, amid global capex from chipmakers like TSMC.[1][3] Long-term tailwinds in AI, EVs, and advanced nodes outweigh near-term China export risks, with the stock's 75% 6-month gain and quality/momentum scores reinforcing upside potential.[2][4]",
      "company_overview": "Applied Materials, Inc. (AMAT) is a leading provider of semiconductor manufacturing equipment, serving advanced chip production for AI, data centers, EVs, and automation, with a market cap of approximately $256 billion and a strong position in the chip-equipment sector.[1][2][4] The stock has delivered robust performance, including a 6-month return of +75.3%, YTD return of 20%, and 81% over the past year, recently surging 6.1% to $322.51 on February 6, 2026, amid AI-driven demand despite broader market declines.[1][2][4] Fundamentals remain solid, with Q4 FY2025 EPS of $2.17 beating estimates, ROE of 39.26%, and a low debt-to-equity ratio of 0.32, though quarterly revenue dipped 3.5% year-over-year.[1]",
      "key_developments": [
        "Stock surged 6.1% to $322.51 on February 6, 2026, with high volume ($2.64B-$8.2M shares), driven by AI demand and analyst upgrades including Citi to $400, Deutsche Bank to $390 (buy), KeyCorp to $380, and Morgan Stanley to $364; consensus is Moderate Buy with $315 average target.[1][2]",
        "Recent insider sale by a senior VP of ~4,000 shares at $238.24, reducing ownership by 4.53%, though not indicative of broader trends.[1]",
        "Stock experienced volatility, falling -2.96% to $318.67 in a prior session amid sector rotation, but maintains momentum with 24 Buy and 8 Hold ratings.[1][5]"
      ],
      "catalysts": [
        "Q1 FY2026 earnings on February 12, 2026, with consensus EPS $2.19 and revenue $6.86-$6.89B; a beat could drive further gains given history of topping estimates.[3][5]",
        "Continued AI capex from hyperscalers and chipmakers, plus potential positive guidance on advanced packaging and next-gen nodes.[2][4]"
      ],
      "risk_factors": [
        "Year-over-year earnings decline expected (-8% EPS, -3.9-4.34% revenue) in upcoming quarter, testing momentum sustainability.[3][5]",
        "U.S.-China export restrictions risking ~$600M revenue, with extended reviews on high-end equipment delaying orders and shipments.[2][4]"
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/applied-materials-nasdaqamat-trading-up-61-whats-next-2026-02-06/",
        "https://www.ainvest.com/news/applied-materials-surges-6-1-ai-driven-demand-ranks-34th-2-64-billion-trading-volume-2602/",
        "https://www.nasdaq.com/articles/applied-materials-amat-expected-beat-earnings-estimates-can-stock-move-higher",
        "https://simplywall.st/stocks/us/semiconductors/nasdaq-amat/applied-materials/news/applied-materials-balances-ai-growth-opportunity-with-new-ch",
        "https://www.zacks.com/stock/news/2828386/heres-why-applied-materials-amat-fell-more-than-broader-market",
        "https://www.tipranks.com/news/applied-materials-stock-amat-plunges-despite-hopes-for-a-more-constructive-direction"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "DHL",
      "name": "Deutsche Post AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 49.7,
      "currency": "EUR",
      "market_cap": 57314856960,
      "pe_ratio": 16.188925,
      "forward_pe": 15.037458,
      "roe": 16.792,
      "dividend_yield": 372.0,
      "momentum_6m": 21.72421879525457,
      "momentum_12m": 48.088536973267004,
      "rsi_14": 73.08786675989094,
      "alpha_score": 69,
      "score_breakdown": {
        "value": 18,
        "quality": 16,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/DHL.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Deutsche Post AG (DHL) is the global market leader in logistics, operating across express delivery, freight forwarding, supply chain solutions, and domestic parcel/mail services in Germany[5]. The company has demonstrated consistent earnings growth through 2025, with Q3 EBIT reaching EUR 1.5 billion (up 7.6% year-over-year) despite revenue headwinds from currency effects and U.S. trade tensions[2]. DHL's strong operational performance and cash generation have positioned it favorably relative to its valuation metrics.",
      "company_overview": "Deutsche Post AG (DHL) is the global market leader in logistics, operating across express delivery, freight forwarding, supply chain solutions, and domestic parcel/mail services in Germany[5]. The company has demonstrated consistent earnings growth through 2025, with Q3 EBIT reaching EUR 1.5 billion (up 7.6% year-over-year) despite revenue headwinds from currency effects and U.S. trade tensions[2]. DHL's strong operational performance and cash generation have positioned it favorably relative to its valuation metrics.",
      "key_developments": [
        "**Q3 2025 Earnings Beat**: EBIT margin expanded to 7.3% (Q3 2024: 6.7%), marking four consecutive quarters of earnings growth through active capacity management and structural cost improvements[2]"
      ],
      "catalysts": [
        "**2026 Full-Year Earnings**: Guidance of at least EUR 6 billion EBIT and approximately EUR 3 billion free cash flow (excluding M&A) provides clear targets; consensus suggests potential upside to EUR 3.35+ EPS[2][3]"
      ],
      "risk_factors": [
        "**Global Forwarding Deterioration**: The 29.6% EBIT decline in Global Forwarding, Freight signals structural weakness in European road freight that may persist if economic conditions worsen; this division represents meaningful earnings exposure[2]"
      ],
      "sources": [
        "https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-financial-figures-q1-2025.html",
        "https://group.dhl.com/en/media-relations/press-releases/2025/dhl-group-financial-figures-q3-2025.html",
        "https://group.dhl.com/en/investors/shares/consensus.html",
        "https://reporting-hub.group.dhl.com/2025-q3/en/business-performance/",
        "https://group.dhl.com/en/investors.html",
        "https://www.marketscreener.com/news/dhl-consensus-full-year-dhl-consensus-fy-2026-2-2-ce7e5bd2d989fe2c",
        "https://israelgives.org/celebs-details/282/How-Deutsche-Post-AG-(DHL)-stock-performs-during-market-turbulence",
        "https://simplywall.st/stocks/de/transportation/etr-dhl/deutsche-post-shares/news/deutsche-post-ag-etrdhl-looks-inexpensive-but-perhaps-not-at"
      ],
      "target_timeframe": "3-6 months"
    }
  ]
}